Regulus Therapeutics Inc. (NASDAQ:RGLS) will be posting its quarterly earnings results after the market closes on Monday, October 30th. Analysts expect Regulus Therapeutics to post earnings of ($0.19) per share for the quarter.

Regulus Therapeutics (NASDAQ:RGLS) last issued its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.31) by ($0.10). The business had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.02 million. Regulus Therapeutics had a negative net margin of 31,460.47% and a negative return on equity of 173.20%. On average, analysts expect Regulus Therapeutics to post $-0.97 EPS for the current fiscal year and $-0.38 EPS for the next fiscal year.

Regulus Therapeutics Inc. (RGLS) opened at 1.21 on Monday. Regulus Therapeutics Inc. has a one year low of $0.79 and a one year high of $3.38. The company’s 50-day moving average is $1.26 and its 200 day moving average is $1.23. The stock’s market capitalization is $125.58 million.

RGLS has been the topic of a number of recent analyst reports. Zacks Investment Research raised shares of Regulus Therapeutics from a “hold” rating to a “buy” rating and set a $1.00 price objective on the stock in a research report on Wednesday, July 12th. Chardan Capital cut shares of Regulus Therapeutics from a “buy” rating to a “neutral” rating in a report on Wednesday, August 2nd. Needham & Company LLC restated a “hold” rating on shares of Regulus Therapeutics in a report on Wednesday, August 2nd. Finally, Wedbush restated an “ourperform” rating and issued a $4.00 target price on shares of Regulus Therapeutics in a report on Monday, August 7th. One research analyst has rated the stock with a sell rating, five have given a hold rating and two have issued a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $3.67.

ILLEGAL ACTIVITY WARNING: “Regulus Therapeutics Inc. (RGLS) to Release Earnings on Monday” was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another domain, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/10/23/regulus-therapeutics-inc-rgls-to-release-earnings-on-monday.html.

In other Regulus Therapeutics news, insider Joseph P. Hagan purchased 219,780 shares of the firm’s stock in a transaction that occurred on Tuesday, July 25th. The stock was purchased at an average price of $0.91 per share, for a total transaction of $199,999.80. Following the purchase, the insider now directly owns 241,297 shares in the company, valued at $219,580.27. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Daniel R. Chevallard purchased 54,945 shares of the firm’s stock in a transaction that occurred on Tuesday, July 25th. The shares were acquired at an average price of $0.91 per share, with a total value of $49,999.95. Following the purchase, the chief financial officer now owns 59,415 shares in the company, valued at $54,067.65. The disclosure for this purchase can be found here. In the last quarter, insiders have purchased 549,450 shares of company stock valued at $500,000. 4.80% of the stock is owned by company insiders.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.

Earnings History for Regulus Therapeutics (NASDAQ:RGLS)

Receive News & Ratings for Regulus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.